Digoxin for relapsed non-WNT non-SHH medulloblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether the drug digoxin can help treat medulloblastoma that has come back after standard treatments like chemotherapy and radiation. Digoxin is a heart medicine being studied for its anticancer effects against a specific type of medulloblastoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 12 months but younger than 30 years old.
- Your medulloblastoma has come back (relapsed) and is a specific subtype called non-WNT, non-SHH.
- You have received at least one round of chemotherapy and radiation therapy in the past.
- You have measurable tumor on an MRI scan (at least a certain size).
- You do not have certain heart conditions or take medications that interfere with digoxin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two standard treatments for a type of brain tumor called SHH-activated medulloblastoma in children under 5. The goal is to see which treatment better protects thinking and learning skills over time.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This Phase 2 study tests DFMO (a maintenance medicine) to help stop medulloblastoma from coming back or worsening after prior treatment. It focuses on children and young people with specific high-risk tumor types or tumors that have returned or not responded well to treatment.
This trial tests a combination of two oral drugs (axitinib and metronomic etoposide) for children and young adults whose medulloblastoma or ependymoma has come back or is not responding to standard therapy. The goal is to see if this daily pill treatment can control tumor growth with manageable side effects.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.